Darunavir/ritonavir and rosuvastatin

Coadministration of darunavir/ritonavir (600/100 mg twice daily) and rosuvastatin (10 mg once daily) was studied in 12 HIV- subjects. The geometric mean AUC for rosuvastatin increased by 48% in the presence of darunavir/ritonavir and Cmax increased by 2.44-fold. There were no significant changes in darunavir or ritonavir AUC or Cmax. Lipid lowering effects of rosuvastatin were not significantly altered, despite higher concentrations of rosuvastatin. There were no adverse events attributable to the interaction.

Source: IAS report (20 July 2010)

Ref: Fichtenbaum C et al. Darunavir/ritonavir increases rosuvastatin concentrations but does not alter lipid-lowering effect in healthy volunteers. 18th IAS Conference, 18–23 July 2010, Vienna. Poster abstract WEPE0101.

Links to other websites are current at date of posting but not maintained.